Thromboembolic Complications in Continuous Versus Interrupted Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation: A Multicenter Study.

Autor:	Miller W; Department of Surgery, University of Minnesota, Minneapolis, MN., Braaten J; Department of Surgery, University of Minnesota, Minneapolis, MN., Rauzi A; Department of Surgery, University of Minnesota, Minneapolis, MN., Wothe J; Department of Surgery, University of Minnesota, Minneapolis, MN.; Department of Critical Care, Abbott Northwestern Hospital, Minneapolis, MN.; Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN.; Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN., Sather K; Department of Surgery, University of Minnesota, Minneapolis, MN., Phillips A; Department of Critical Care, Abbott Northwestern Hospital, Minneapolis, MN., Evans D; Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN.; Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN., Saavedra-Romero R; Department of Critical Care, Abbott Northwestern Hospital, Minneapolis, MN., Prekker M; Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN.; Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN., Brunsvold ME; Department of Surgery, University of Minnesota, Minneapolis, MN.
Jazyk:	angličtina
Zdroj:	Critical care explorations [Crit Care Explor] 2024 Sep 25; Vol. 6 (10), pp. e1155. Date of Electronic Publication: 2024 Sep 25 (Print Publication: 2024).
DOI:	10.1097/CCE.0000000000001155
Abstrakt:	Objectives: Continuous, therapeutic anticoagulation is the standard of care for patients on extracorporeal membrane oxygenation (ECMO). The risks of hemorrhage exacerbated by anticoagulation must be weighed with the thrombotic risks associated with ECMO. We hypothesized increased thrombotic events in patients who had interrupted (vs. continuous) anticoagulation during venovenous ECMO. Design: This is a retrospective, observational study. Setting: Enrollment of individuals took place at three adult ECMO centers in Minnesota from 2013 to 2022. Patients: This study consists of 346 patients supported with venovenous ECMO. Interventions: Anticoagulation administration was collected from electronic health records, including frequency and duration of anticoagulation interruptions (IAs) and timing and type of thrombotic events, and data were analyzed using descriptive statistics. Measurements and Main Results: A total of 156 patients had IA during their ECMO run and 190 had continuous anticoagulation. Risk adjusted logistic regression demonstrated that individuals in the IA group were not statistically more likely to experience a thrombotic complication (odds ratio [OR], 0.69; 95% CI, 0.27-1.70) or require ECMO circuit change (OR, 1.36; 95% CI, 0.52-3.49). Subgroup analysis demonstrated greater frequency of overall thrombotic events with increasing frequency and duration of anticoagulation being interrupted (p = 0.001). Conclusions: Our multicenter analysis found a similar frequency of thrombotic events in patients on ECMO when anticoagulation was interrupted vs. administered continuously. Further investigation into the impact of the frequency and duration of these interruptions is warranted. Competing Interests: The authors have disclosed that they do not have any potential conflicts of interest. (Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu